SARS‐CoV‐2 nucleocapsid protein intranasal inoculation induces local and systemic T cell responses in mice

He, Jia; Huang, Jingru; Zhang, Yaolin; Zhang, Jiyan

doi:10.1002/jmv.26769

Cited by 25 publications

(27 citation statements)

References 12 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… Type Vaccine Target Route (no. of doses) Animal used Ad-vectored vaccine ChAd-SARS-CoV-2-S S protein IN (1) hACE2 mice 33 , 43 and rhesus macaques 42 ChAd-SARS-CoV-2-S S protein IM or IN, (1) Golden Syrian hamsters 35 AdCOVID RBD protein IN (1) Mice 44 Ad5.SARS-CoV2-S1 S1 protein IN or SC, (1) Mice 45 ChAdOx1 S protein IM or IN, (1 or 2) Ferrets 47 , hamsters and rhesus macaques 46 Ad5-nCoV Full-length S protein IM or IN, (1); or oral + IN, simultaneously, (1) Mice and ferrets 38 Ad5-S-nb2 S protein IM or IN, (1) Mice and rhesus macaques 39 Ad5‐N N protein IN (2) Mice 52 AdC7-S, AdC7-RBD and AdC7-RBD-tr2 S, RBD or tandem-repeat dimeric RBD IM or IN, (2) hACE2 mice 50 – S and N proteins SC or IN, (1) Mice 51 Lentivirus-vectored vaccine – S protein IP + IN (2); or IM + IN (2) Mice and golden hamsters 57 – S protein IM + IN, (2) hACE2 mice 58 Influenza virus-vectored vaccine ∆NA(RBD)-Flu virus RBD pro...…”

Section: Recent Progress In the Development Of Intranasal Covid-19 Vaccinesmentioning

confidence: 99%

Intranasal COVID-19 vaccines: From bench to bed

Alu¹,

Chen²,

et al. 2022

View full text Add to dashboard Cite

Currently licensed COVID-19 vaccines are all designed for intramuscular (IM) immunization. However, vaccination today failed to prevent the virus infection through the upper respiratory tract, which is partially due to the absence of mucosal immunity activation. Despite the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, the next generation of COVID-19 vaccine is in demand and intranasal (IN) vaccination method has been demonstrated to be potent in inducing both mucosal and systemic immune responses. Presently, although not licensed, various IN vaccines against SARS-CoV-2 are under intensive investigation, with 12 candidates reaching clinical trials at different phases. In this review, we give a detailed description about current status of IN COVID-19 vaccines, including virus-vectored vaccines, recombinant subunit vaccines and live attenuated vaccines. The ongoing clinical trials for IN vaccines are highlighted. Additionally, the underlying mechanisms of mucosal immunity and potential mucosal adjuvants and nasal delivery devices are also summarized.

show abstract

Section: Recent Progress In the Development Of Intranasal Covid-19 Vaccinesmentioning

confidence: 99%

Intranasal COVID-19 vaccines: From bench to bed

Alu¹,

Chen²,

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In the COVID-19 context, the main transgene of choice has been the SARS-CoV-2 structural surface glycoprotein-coding gene (spike protein), either whole or partial [16]. Nonetheless, the nucleocapsid protein (N) has also been the target of some studies, either alone or in combination with the S protein [17][18][19].…”

Section: The "Trojan Horse" Technologymentioning

confidence: 99%

The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis

Silva

Fonseca

2021

Vaccines

View full text Add to dashboard Cite

The COVID-19 pandemic represents a milestone in vaccine research and development in a global context. A worldwide effort, as never seen before, involved scientists from all over the world in favor of the fast, accurate and precise construction and testing of immunogens against the new coronavirus, SARS-CoV-2. Among all the vaccine strategies put into play for study and validation, those based on recombinant viral vectors gained special attention due to their effectiveness, ease of production and the amplitude of the triggered immune responses. Some of these new vaccines have already been approved for emergency/full use, while others are still in pre- and clinical trials. In this article we will highlight what is behind adeno-associated vectors, such as those presented by the immunogens ChaAdOx1, Sputnik, Convidecia (CanSino, Tianjin, China), and Janssen (Johnson & Johnson, New Jersey, EUA), in addition to other promising platforms such as Vaccinia virus MVA, influenza virus, and measles virus, among others.

show abstract

“…Although the majority of vaccines in development are focused on the S protein, the SARS-CoV-2 N protein has also been proposed as a promising vaccine component (Dutta et al, 2020). Studies have shown that the N protein of SARS-CoV-2 can elicit strong humoral and cellular immunity (Ferretti et al, 2020;He et al, 2021;Ni et al, 2020). Notably, a recent study by Dangi et al (2021) found that a spike-based vaccine does not provide acute protection to the central nervous system; however, only when co-administered with a spike-based vaccine and a nucleocapsid-based vaccine, protection against distal viral dissemination to the nervous system was observed.…”

Section: Introductionmentioning

confidence: 99%